source
- Frazier Life Sciences nets $1.1B in long-running fund aimed at small, midsize biotechsFrazier Life Sciences (FLS) has stacked up another sizable biotech-focused capital commitment, netting more than $1.1 billion for its long-running public fund.Fierce Biotech · 6h ago↗ source
- Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3Beeline Medicines announced that its oral small-molecule inhibitor afimetoran achieved the primary endpoint in a 48-week Phase 2 trial in patients with systemic lupus erythematosus (SLE). The tria…